RLAY today
$18.02-$0.06 (-0.33%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bullish
15 minBullish
5 minSymmetric Triangle
Daily trend turns down below $16.52
Key levels
Resistance$20.96
Resistance$19.03
Support$17.71
Support$16.52
Latest news & SEC filings
AnalystJones Trading keeps Buy rating on Relay Therapeutics, lifts target to $31
EarningsRelay Therapeutics Posts Third-Quarter 2026 Results
SEC FilingRelay Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All RLAY news →About Relay Therapeutics
Relay Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for cancer and genetic diseases. Its lead product candidate, zovegalisib, targets mutant PI3Kα and is being studied in breast cancer, solid tumors, and PIK3CA-related overgrowth spectrum. The company also has programs including an NRAS-selective inhibitor and a chaperone for Fabry disease. Its customers are patients and healthcare providers, and it operates in the United States.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Relay Therapeutics, Inc. (RLAY)
What Is the Price Target for RLAY?
SEPT Low Target
$22.10
SEPT Mid Target
$26.00
SEPT High Target
$29.90
Analyst Consensus
$26.00
Is RLAY a Buy or Sell Right Now?
Thesis
- •Revenue growing 53.4% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RLAY.
Start Free Trial →Is RLAY Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$26.12
27
Moat Score
NONE
4/9
Piotroski Score
29.4
Altman Z-Score
What Is Smart Money Doing with RLAY?
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bergstrom Donald A | officer | Sale | 2,252 | $42K | Oct 28, 2026 |
| Rahmer Peter | officer | Sale | 753 | $14K | Oct 28, 2026 |
| Catinazzo Thomas | officer | Sale | 1,469 | $27K | Oct 28, 2026 |
| Patel Sanjiv | director officer | Sale | 48,199 | $872K | Oct 7, 2026 |
| Catinazzo Thomas | officer | Sale | 17,511 | $325K | Oct 6, 2026 |
| Catinazzo Thomas | officer | Sale | 206 | $4K | Oct 6, 2026 |
| Bergstrom Donald A | officer | Sale | 8,530 | $162K | Sep 8, 2026 |
| Rahmer Peter | officer | Sale | 4,508 | $90K | Aug 26, 2026 |
| SVF Pauling (Cayman) Ltd | 10% owner | Sale | 6,000,000 | $116.4M | Aug 25, 2026 |
| Bergstrom Donald A | officer | Sale | 8,660 | $162K | Jul 6, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RLAY Growth Story
Revenue YoY
53.4%
3yr Revenue CAGR
N/A%
EPS Growth YoY
31.78%
FCF Growth YoY
6.1%
Revenue Trend
ACCELERATING
Dark Pool Trades for RLAY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RLAY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:25:42 | $18.01 | 1,200 | $$22K | SELL |
| 19:24:35 | $18.11 | 1,300 | $$24K | SELL |
| 19:24:35 | $18.11 | 1,300 | $$24K | SELL |
| 17:51:32 | $18.15 | 1,800 | $$33K | BUY |
| 17:15:44 | $18.08 | 3,165 | $$57K | SELL |
5 dark pool trades shown · $$159K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RLAY
PREVIEWSEPT Investing provides real-time options flow tracking for RLAY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $19 | Dec 18 | 35 | $$500 | 4 | SWEEP |
| PUT | $19 | Dec 18 | 35 | $$195 | 1 | SWEEP |
| PUT | $19 | Dec 18 | 35 | $$210 | 1 | SWEEP |
3 options trades shown · 33% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About RLAY
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for RLAY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $RLAY -- Neutral RLAY at $15.87. Day range $15.60-$16.29. Last candle: shooting star (20% buying). Price at zone support $15.69 — reversed 3/3 times. Buyers active within 90 days, likel...
Join 3,500+ traders discussing RLAY in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Relay Therapeutics, Inc. (RLAY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RLAY — frequently asked questions
What is RLAY stock price today?
Relay Therapeutics, Inc. (RLAY) is at $18.02, down 0.33% (-$0.06) at the Nov 13, 2026 close.
Why is RLAY stock moving today?
Latest RLAY news — Nov 6, 2026: Jones Trading keeps Buy rating on Relay Therapeutics, lifts target to $31 · Nov 4, 2026: Relay Therapeutics Posts Third-Quarter 2026 Results
What is the RLAY price target?
The average analyst price target for RLAY is $26.00, ranging from $18 to $31, based on 11 analysts. Latest: HC Wainwright & Co. maintains on Aug 20, 2026.
What do analysts rate RLAY?
Analyst ratings for RLAY: 0 Buy, 19 Hold, 0 Sell — consensus Hold.
Did RLAY beat earnings?
RLAY last reported on Aug 6, 2026: EPS -$0.41 vs -$0.39 expected — a miss of 4.8%.
Does RLAY pay a dividend?
RLAY does not currently pay a dividend.
What are RLAY support and resistance levels?
Support: $17.71, $16.52, $14.78. Resistance: $19.03, $20.96.
What are insiders doing with RLAY?
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
What is the latest news on RLAY?
Nov 6, 2026: Jones Trading keeps Buy rating on Relay Therapeutics, lifts target to $31 · Nov 4, 2026: Relay Therapeutics Posts Third-Quarter 2026 Results · Nov 4, 2026: Relay Therapeutics, Inc. filed a report on a major company event (Form 8-K)